• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SWK Holdings Appoints Jerry Albright to Board of Directors

    3/15/23 4:05:00 PM ET
    $SWKH
    Diversified Financial Services
    Finance
    Get the next $SWKH alert in real time by email

    DALLAS, March 15, 2023 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that Jerry Albright has been named to the Company's Board of Directors and will replace Wendy DiCicco, who chose not to seek re-election to the Board because of external professional commitments.  The transition will be effective March 15, 2023, with Mr. Albright joining Board Chair, Laurie Dotter, and directors, Robert K. Hatcher, and Marcus Pennington, on the Board.  

    "We are pleased to welcome Jerry to SWK's Board of Directors and look forward to benefitting from his extensive investment and banking experience as we continue to target opportunities to maximize SWK's position as a partner of choice for small- and mid-sized healthcare companies seeking non-dilutive financing to fuel growth," stated Ms. Dotter. "We believe Jerry's expertise in board protocols and practices should allow for a seamless transition from Ms. DiCicco, who has served on our Board since February 2022. During her tenure, Wendy provided valuable industry insights to the management team and her colleagues on the Board and was instrumental in revamping our executive compensation program, which now more closely aligns our management team with shareholders. On behalf of the leadership team and Board, we thank Wendy for her contributions."

    Mr. Albright is currently a managing partner of ADIM, LLC, an investment management firm specializing in establishing protocols, policies, and practices for boards of directors.  Prior to ADIM, Mr. Albright held multiple roles of increasing responsibility at the Teacher Retirement System of Texas ("TRS") for nearly three decades until his retirement in May 2020, including as TRS Investment Division's Deputy Chief Investment Officer, Chief Operating Officer, Director of Investment Operations and, most recently, as its Chief Investment Officer, in which capacity he served from mid-2017 until his retirement.  Prior to joining TRS, Mr. Albright was the Executive Vice President and a member of the board of directors of a multi-bank holding company in Texas, in addition to serving as a director on the board of two affiliated banks.  Mr. Albright has also previously served on the Advisory Board of the Finance Department at Texas A&M University. Mr. Albright holds a bachelor's degree in economics from Texas A&M University.

    "Jerry is an excellent addition to the Board and arrives at a time of opportunity for SWK given the dynamics within the capital markets that we believe continue to make our suite of financing solutions enticing to life science companies in need of capital," stated Mr. Hatcher.  "We wish Wendy the very best as she continues to serve as an advisor to companies in the healthcare sector, including SWK portfolio companies."

    About SWK Holdings Corporation

    SWK Holdings Corporation is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from $5.0 million to $25.0 million.  SWK also owns Enteris BioPharma, whose Peptelligence® and ProPerma® drug delivery technologies create oral formulations of peptide-based and BCS class II, III, and IV small molecules. Additional information on the life science finance market is available on the Company's website at www.swkhold.com.

    Safe Harbor Statement

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors which, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

    Cision View original content:https://www.prnewswire.com/news-releases/swk-holdings-appoints-jerry-albright-to-board-of-directors-301773310.html

    SOURCE SWK Holdings Corporation

    Get the next $SWKH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SWKH

    DatePrice TargetRatingAnalyst
    12/28/2022$26.00Buy
    Lake Street
    4/18/2022$26.00Buy
    Lake Street
    More analyst ratings

    $SWKH
    Financials

    Live finance-specific insights

    See more
    • SWK Holdings Corporation Announces Financial Results for Third Quarter 2024

      Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CSTCorporate HighlightsThird quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023.Third quarter 2024 finance receivables segment adjusted non-GAAP net income was $5.0 million, compared with adjusted non-GAAP net income of $5.8 million for the third quarter 2023.As of September 30, 2024, net finance receivables were $255.9 million, a 14.4% increase from September 30, 2023.The third quarter 2024 effective yield was 14.6%, a 60 basis points increase from third quarter 2023.As of September 30, 2024, GAAP book value per share was $22.94, a 3.7% increase from $2

      11/14/24 4:15:00 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SWK Holdings Provides Portfolio Update

      Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results

      10/17/24 4:15:00 PM ET
      $BTCY
      $DERM
      $ELUT
      $ETON
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

      7/17/24 4:15:00 PM ET
      $BIOL
      $BTCY
      $DERM
      $ELUT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)

    $SWKH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ImpediMed Secures $15m Growth Capital Funding

      New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Funds raised will provide ImpediMed with funding flexibility and will be used to support growth and commercialization activities. Armentum Partners acted as the Company's exclusiv

      2/7/25 11:00:00 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • SWK Holdings Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / January 6, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update for material events occurring since September 30, 2024.OriginationsIn November, SWK advanced $5.0M to existing borrower Journey Medical to help fund the company's launch of EmrosiTM.In November, as part of a broader amendment SWK advanced $0.6M to existing borrower Biotricity. On amendment closing, SWK received 600,000 warrants to purchase Biotricity stock at $0.50 per share.In December, SWK closed an $8.0M senior secured term loan with Triple

      1/6/25 7:35:00 AM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT Staggs Joe David Jr exercised 33,750 shares at a strike of $11.22 and covered exercise/tax liability with 25,857 shares, increasing direct ownership by 7% to 123,766 units (SEC Form 4)

      4 - SWK Holdings Corp (0001089907) (Issuer)

      4/17/25 4:34:14 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • PRESIDENT Staggs Joe David Jr was granted 36,700 shares, increasing direct ownership by 46% to 115,873 units (SEC Form 4)

      4 - SWK Holdings Corp (0001089907) (Issuer)

      2/4/25 4:14:55 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Chief Financial Officer Rice Adam was granted 9,175 shares, increasing direct ownership by 151% to 15,247 units (SEC Form 4)

      4 - SWK Holdings Corp (0001089907) (Issuer)

      2/4/25 4:14:24 PM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street resumed coverage on SWK Holdings with a new price target

      Lake Street resumed coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

      12/28/22 9:18:49 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Lake Street initiated coverage on SWK Holdings with a new price target

      Lake Street initiated coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

      4/18/22 8:44:23 AM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    SEC Filings

    See more
    • SWK Holdings Corporation filed SEC Form 8-K: Other Events

      8-K - SWK Holdings Corp (0001089907) (Filer)

      5/19/25 8:47:29 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SWK Holdings Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - SWK Holdings Corp (0001089907) (Filer)

      5/15/25 4:23:24 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SWK Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SWK Holdings Corp (0001089907) (Filer)

      5/15/25 4:22:48 PM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SWK Holdings Corporation

      SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

      11/14/24 11:49:47 AM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Amendment: SEC Form SC 13D/A filed by SWK Holdings Corporation

      SC 13D/A - SWK Holdings Corp (0001089907) (Subject)

      10/25/24 4:05:56 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • SEC Form SC 13G/A filed by SWK Holdings Corporation (Amendment)

      SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

      2/14/24 2:14:12 PM ET
      $SWKH
      Diversified Financial Services
      Finance

    $SWKH
    Leadership Updates

    Live Leadership Updates

    See more
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • SWK Holdings Appoints Chief Financial Officer

      Company Also Promotes Controller DALLAS, TX / ACCESSWIRE / July 8, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, is pleased to announce the appointment of Adam C. Rice, CPA, as Chief Financial Officer (CFO) of the company and the promotion of Courtney Baker, CPA, to Controller.With over 18 years of senior-level finance and accounting leadership experience, Rice has led financial operations management, corporate financial planning and analysis, strategic planning and financial statement reporting. He was previously CFO of Park Cities Asset Management, an SEC

      7/8/24 5:00:00 PM ET
      $SWKH
      Diversified Financial Services
      Finance
    • Stanley Black & Decker Appoints Chris Nelson Chief Operating Officer and Executive Vice President and President of Tools & Outdoor

      NEW BRITAIN, Conn., May 2, 2023 /PRNewswire/ -- Stanley Black & Decker (NYSE:SWK) today announced the appointment of Chris Nelson as Chief Operating Officer of the company, and Executive Vice President and President of Tools & Outdoor, effective June 14, 2023. Nelson joins Stanley Black & Decker from Carrier Corporation and brings more than 25 years of leadership experience in general management, product development and innovation, and growth transformation. Nelson will report to Donald Allan Jr., President and CEO of Stanley Black & Decker. He will assume the role of President, Tools & Outdoor, from current Acting Co-Presidents Robert Raff and John Wyatt. Raff will continue to serve as Chie

      5/2/23 4:36:00 PM ET
      $SWK
      $SWKH
      Industrial Machinery/Components
      Consumer Discretionary
      Diversified Financial Services
      Finance